Antimony determination in tissues and serum of hamsters infected with<i>Leishmania garnhami</i>and treated with meglumine antimoniate

Yarbuh, Ana Lugo de; Áñez, Néstor; Peña, Yaneira Petit de; Burguera, J.L.; Burguera, M.

doi:10.1080/00034983.1994.11812832

Cited by 20 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, leading to considerable concentrations of Sb 3+ in body fluids as suggested previously 43 . This finding supports the hypothesis that the formation of Sb 3+ may be responsible for both the observed longterm toxicity of the drug and its therapeutic action 32 .…”

Section: +mentioning

confidence: 57%

Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate

Schubach

Marzochi

Moreira

et al. 2005

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

We retrospectively analyzed a series of 151 cases of cutaneous leishmaniasis treated between 1967 and 1982. One-hundred-and-thirty-nine (92%) patients presented with active lesions and were treated with daily doses of meglumine antimoniate: 81 adults received a 5-ml vial IM and 58 children received 1 to 5ml. Forty-five (32.4%) patients underwent continuous treatment with meglumine antimoniate for 25 to 116 days without rest intervals, and 94 (67.6%) intermittent treatment with 2 to 5 series of meglumine antimoniate. Intermittent series could include schedules of daily IM applications for 10 to 25 days each and intervals varying from 10 to 60 days. Antimony dose was calculated for 66 (47.5%) patients and ranged from 3.9 to 28.7 Sb5+/kg/day. Of these, 35 patients received >10mg and 31 patients <10mg Sb5+/kg/day. Median time of healing was longer for lesions on the legs and feet - 67.5 days versus 48.7 days (p < 0.001) for other sites. However, there were no significant differences in the median time of healing between adults and children, intermittent and continuous regimens or high and low antimony doses. Fifty-one patients were reassessed 5 to 14 years after treatment and showed no evidence of disease. These results support further investigation (clinical trials) on treatment using low doses of antimony.

show abstract

Section: +mentioning

confidence: 57%

Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate

Schubach

Marzochi

Moreira

et al. 2005

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

Biological Chemistry of Antimony and Bismuth

Yang

Sun

2010

Biological Chemistry of Arsenic, Antimony and Bismuth

View full text Add to dashboard Cite

The influence of some triphenylantimony(V) catecholates and o‐amidophenolates on lipid peroxidationin vitro

Smolyaninov

Antonova

Poddel’sky

et al. 2012

Applied Organom Chemis

View full text Add to dashboard Cite

A number of catecholates (complexes 1-3, 6) and o-amidophenolates (complexes 4, 5) of triphenylantimony(V) was examined in the process of lipid peroxidation of liver homogenates and sperm of Russian sturgeon (Acipenser gueldenstaedti B.), and human red blood cells. It was shown that the influence of complexes 1-6 on lipid peroxidation process in model systems depends on the nature of redox-active ligand and varies from weak anti-and pro-oxidant (catecholates 1, 6) to pronounced antioxidant (catecholates and o-amidophenolates 2-5). It was found that the complexes 2-5 are the more effective inhibitors of lipid peroxidation than standard antioxidant ionol.

show abstract

Antimony determination in tissues and serum of hamsters infected withLeishmania garnhamiand treated with meglumine antimoniate

Cited by 20 publications

References 9 publications

Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate

Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate

Biological Chemistry of Antimony and Bismuth

The influence of some triphenylantimony(V) catecholates and o‐amidophenolates on lipid peroxidationin vitro

Contact Info

Product

Resources

About